O presente documento fornece orientações aos Estados-Membros da União Africana sobre as acções a empreender para garantir que continuam a satisfazer todos os requisitos em matéria de saúde
necessidades dos seus cidadãos, de acordo com a realização dos objectivos da Estratégia de Saúde p...ara África 2016 - 2030.
more
Arabic Version of Guidance for the continuation of essential health services during COVID-19 pandemic
Este documento fornece orientações aos Estados-Membros da União Africana sobre considerações fundamentais em matéria de saúde mental e apoio psicossocial (MHPSS) em relação à pandemia de coronavírus de 2019 (COVID-19). Contém orientações úteis sobre o MHPSS para a comunidade, profissi...onais de saúde, prestadores de cuidados de saúde a populações vulneráveis e pessoas em quarentena, isolamento ou centros de tratamento(1)
(2). Estas orientações têm como objectivo proporcionar medidas práticas para reduzir o stress, a ansiedade, o estigma e as perturbações psicológicas associadas à COVID-19 e melhorar a saúde mental e o bem-estar em geral. Estas orientações podem ser utilizadas para fins de planeamento por decisores políticos e ministérios de
saúde e instituições que coordenam a resposta de emergência à resposta da COVID-19 por parte dos Estados-Membros. Pode também ser divulgada às partes interessadas.
more
Arabic Version of Guidance for mental health and psychosocial support for COVID-19
O presente documento fornece orientações aos Estados-Membros da União Africana com base num pedido específico dos Estados-Membros de uma lista de controlo/orientação dos equipamentos de protecção individual (EPI) necessários aos profissiona...is de saúde e prestadores de cuidados para a pandemia da doença de Coronavírus de 2019 (COVID-19). Este documento foi sintetizado a partir dos dados actualmente disponíveis (1-6), tendo em conta o contexto africano e, como tal, pode ser adaptado ao contexto do país.
more
Arabic Version of COVID-19 Guidance on use of personal protective equipment for different clinical settings and activities
]. تختلف مخاطر التلوث COVID-19المادية في سياق جائحة مرض فيروس كـــورونـا المستجد [السطحي وانتقال العدوى باختلاف نوع الإعداد وحجم السكان الذين يترددون على كل مكان (مثل: م...افق الرعاية الصحية، والنقل العام، وغيرها من المرافق / أماكنيوضح هذا الدليل بالتفصيل المبادئ والإجراءات الأساسية للتطهير التي ينبغي اتباعها لتطهير البيئة العمل المزدحمة)، على الرغم من أن ا لعدم قدرتنا على تغطية كل موقف هنا، فإنه من الممكن ًمبادئ التطهير البيئي تظل كما هي. ونظرالقيام بتكييف هذا الدليل مع المواقف الفردية عند ظهورها. يركز هذا الدليل على كيفية تنفيذ عملية ، والذي تم )۱(ا وينبغي تقديمه كجزء من برنامج مخطط له ومحسوب المواردًإزالة التلوث البيئي عملي.]COVID-19دمجه بالكامل مع جهود الاستجابة الأخرى لمرض فيروس كـــورونـا المستج
more
The "Prediabetes Risk Test" is a tool designed to help individuals assess their risk for prediabetes and type 2 diabetes. The test uses a point-based system with questions about age, gender, family history of diabetes, history of high blood pressure..., physical activity level, and weight category. Based on the total score, individuals with a score of 5 or higher are at an increased risk of prediabetes, meaning their blood sugar levels may be elevated but not yet high enough to be classified as type 2 diabetes. The test encourages individuals with a high score to consult a doctor for further testing and suggests lifestyle changes as a preventive measure. Special risk considerations are provided for certain ethnic groups, such as African American, Hispanic/Latino, American Indian, Alaska Native, Asian American, and Pacific Islander populations.
more
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...de la COVID-19 par le public dans les États membres de l’Union africaine. Actuellement, il n’y a : 1. Aucune preuve scientifique provenant d’études précliniques sur l’effet thérapeutique de l’ivermectine pour le traitement de COVID-19 2. Aucune preuve de son efficacité clinique pour la prise en charge de patients présentant une COVID-19 asymptomatique, légère, modérée ou sévère 3. Aucune donnée de sécurité concernant l’utilisation de l’ivermectine pour la COVID-19 dans la majorité des études publié
more
Biosafety involves the implementation of containment principles, technologies and practices to prevent unintentional exposure to biological agents. Biosecurity involves the protection, control and accountability of biological materials and informati...on related to these materials and dualuse research, to prevent their unauthorized access, loss, theft, misuse, diversion or intentional release.
more
Les Centres africains de contrôle et de prévention des maladies (Africa CDC) ont pris connaissance des communiqués de presse concernant les résultats préliminaires d'un vaste essai clinique ran...domisé mené au Royaume-Uni, qui incluait la dexaméthasone, un corticostéroïde, parmi les médicaments utilisés pour le traitement des patients atteints de COVID-19. Les chercheurs ont rapporté que l'administration de dexaméthasone par voie orale ou injectable a permis de réduire d'environ un tiers la mortalité chez les patients COVID-19i qui nécessitaient une ventilation mécanique et d'environ un cinquième chez les patients nécessitant de l'oxygène. Depuis la publication de ces rapports médiatiques, les autorités sanitaires du Royaume-Uni et d'Afrique du Sud ont adopté la dexaméthasone pour le traitement des patients atteints de formes graves de COVID-19
more
ASLM in collaboration with the Africa Centres for Disease Control and Prevention, and in partner...ship with the Clinton Health Access Initiative, Amref and Last Mile Health present the Quality Assurance Framework for SARS-CoV-2 Antigen Rapid Testing for Diagnosis of COVID-19. This framework aims to provide general technical guidance to African Union Members States on the rollout, establishment, implementation, monitoring, and evaluation of SARS-CoV-2 Ag RDT interventions so as to effectively and efficiently detect, control and minimise errors in the performance of COVID-19 laboratory testing processes. It describes the core components for quality assurance, resources mobilisation and advocacy for scale up, monitoring, evaluation, learning and accountability for SARS-CoV-2 implementation.
more
Mars 2020. Recommendations selon les differentes phases
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) ...for the Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac, the Africa Union and Africa CDC’s Regulatory Taskforce has endorsed the Emergency Use Authorisation for the vaccine (see scenario #1). As such, African Union Member States are recommended to waive any review processes and rely directly on the WHO EUL via the AVAREF managed pathway described in Scenario #1
more